

1 Functional status, mood state, and physical activity among women with post-acute COVID-19 syndrome

2

3 ^{1,2}Stephen J. Carter, ¹Marissa N. Baranaukas, ¹John S. Raglin, ²Bernice A. Pescosolido, ²Brea L. Perry

4

5 ¹Department of Kinesiology, School of Public Health – Bloomington, Indiana University; Bloomington,

6 Indiana 47405 USA; ²Department of Sociology, College of Arts and Sciences, Indiana University;

7 Bloomington, IN 47405 USA.

8

9

10 The present work was funded, in part, by the Indiana Clinical and Translational Sciences Institute by grant

11 number UL1TR002529 from the NIH National Center for Advancing Translational Sciences, Clinical and

12 Translational Sciences Award.

13

14 *The authors have no perceived or potential conflicts of interest, financial or otherwise to declare.*

15

16 Corresponding Author:

17

18 Stephen J. Carter, M.S., Ph.D.

19 Assistant Professor

20 Department of Kinesiology

21 School of Public Health – Bloomington

22 Indiana University

23 1025 E 7th Street Suite 044

24 Phone: 1.812.855.6593

25 Email: stjcarte@iu.edu

26

27

28

29

30

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

ABSTRACT

Objectives: While organ-specific pathophysiology has been well-described in SARS-CoV-2 infection, less is known about the attendant effects on functional status, mood state and leisure-time physical activity (PA) in post-acute COVID-19 syndrome.

Methods: A case-control design was employed to recruit 32 women ($n = 17$ SARS-CoV-2; $n = 15$ controls) matched on age (54 ± 12 years), body mass index (27 ± 6 kg/m²), smoking status, and history of cardiopulmonary disease. Participants completed a series of assessments including the Modified Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ-M), Profile of Mood States (POMS), and Godin-Shephard Leisure-Time PA.

Results: SARS-CoV-2 participants exhibited poorer functional status ($p = 0.008$) and reduced leisure-time PA ($p = 0.004$) compared to controls. Significant between-group differences were also detected for the POMS total mood disturbance with sub-scale analyses revealing elevated tension, confusion, and lower vigor among SARS-CoV-2 participants (all p -values < 0.05). The number of SARS-CoV-2 symptoms (e.g., loss of taste / smell, muscle aches etc.) were associated ($r = 0.620$, $p = 0.008$) with confusion.

Conclusion: The sequela of persistent SARS-CoV-2 symptoms elicit clear disturbances in functional status, mood state, and leisure-time PA among women with post-acute COVID-19 syndrome.

Key words: cognitive health, mental health, profile of mood states, mobility, SARS-CoV-2, walking

59 INTRODUCTION

60 Worldwide estimates indicate over 300 million individuals have been diagnosed with severe acute
61 respiratory syndrome coronavirus 2 (SARS-CoV-2), with the United States accounting for approximately
62 20% of total cases [1]. Though vaccination efforts have reduced mortality incidence, emerging hot spots
63 and SAR-CoV-2 variants remain a significant threat to personal and public health [2]. Recent data reveals
64 some individuals experience a delayed recovery with symptoms persisting three to four weeks (or longer)
65 beyond initial SARS-CoV-2 diagnosis – a condition now recognized as post-acute COVID-19 syndrome [3].
66 Among these individuals, latent effects vary considerably but generally include dyspnea, fatigue, mental
67 fog and/or sensory disturbances. Understandably, such complications bear clinical and practical relevance
68 for health and wellness as the number of individuals experiencing lingering SARS-CoV-2-related symptoms
69 grows. While studies have widely characterized clinical outcomes among individuals hospitalized with
70 severe-to-critical SARS-CoV-2 infection – most recover from the acute effects of the virus. Interestingly,
71 illness severity following primary infection, does not appear to be associated with the possibility of longer-
72 term SARS-CoV-2 symptoms [4].

73 Recent data from the Mayo Clinic's COVID-19 Activity Rehabilitation Program indicate women
74 outnumber men 3 to 1 in pursuit of treatment for post-acute COVID-19 syndrome [5]. In France, a similar
75 proportion (sex ratio 4:1) has been reported in women approximately 40 years of age seeking treatment for
76 longer-term SARS-CoV-2 symptoms [6]. This, in turn, raises important questions about the presentation
77 and functional consequences of post-acute COVID-19 syndrome in women – especially since women tend
78 to exhibit greater rates of age-related disability than men [7].

79 A regrettable consequence of the on-going COVID-19 pandemic involves extensive disruption in
80 daily routines affecting work and leisure-time activities [8]. Government lockdowns have restricted public
81 life such that, compared to pre-restriction levels, self-reported physical activity (PA) was reduced by 41%
82 in a multi-national cohort [9]. It is currently unknown whether some of the reduction in PA may be attributable
83 to longer-term effects of SARS-CoV-2 among infected persons. Owing to the systemic psychological
84 benefits of leisure-time PA on variables such as mood state, declining PA may have a negative impact on
85 psychological well-being, including anxiety and depression. Smith and colleagues have shown poorer
86 mental health during the COVID-19 pandemic correlates with being female, younger age, a lower annual

87 income, and having multiple comorbidities [10]. Despite the extensive literature describing the serious
88 physical effects of the SARS-CoV-2 virus in vulnerable populations, little is known about possible
89 relationships between functional status, mood state, and PA behavior in post-acute COVID-19 syndrome.

90 Undoubtedly, the progressive burden of SARS-CoV-2 warrants further investigation into the
91 consequences of post-acute COVID-19 syndrome. Therefore, the present work compared functional status,
92 mood state, and leisure-time PA in women with and without a history of SARS-CoV-2 matched for age and
93 body mass index (BMI). We hypothesized that SARS-CoV-2 participants would have: 1) poorer functional
94 status, 2) greater mood disturbance, and 3) report less leisure-time PA compared to women without a
95 history of SARS-CoV-2. Such information may inform targeted interventions designed to attenuate the
96 burdens of post-acute COVID-19 syndrome in women.

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115 METHODS

116 *Participants*

117 Women *at least* four weeks to four months from having a positive laboratory test for SARS-CoV-2
118 and women without a history of SARS-CoV-2 (i.e., controls) were enrolled in a case-control design. Eligible
119 participants recruited from the community within a 115-mile radius of Bloomington, Indiana were matched
120 on age and BMI. Exclusion criteria were individuals < 18 or > 75 years of age, BMI < 18.5 kg/m² or > 50
121 kg/m², currently pregnant, lactating or trying to become pregnant, documented history of pulmonary disease
122 and/or self-reported use of tobacco products within the previous six months. SARS-CoV-2 participants met
123 the criteria for mild-to-moderate illness severity as defined by the National Institutes of Health [11].
124 Consistent with the working definition of post-acute COVID-19 syndrome reported by Datta et al. [12] and
125 Greenhalgh et al. [13], all SARS-CoV-2 participants (apart from one) reported symptoms beyond 3-4 weeks
126 from initial illness onset. The single ($n = 1$) SARS-CoV-2 participant that did not meet the definition of post-
127 acute COVID-19 syndrome reported a loss of taste and smell lasting 20 days, and as such, were included
128 in statistical analyses. For exploratory purposes, sub-analyses were performed by dichotomizing the SARS-
129 CoV-2 participants by those who were reporting symptoms at the time of testing (i.e., symptomatic) versus
130 those who were not (i.e., asymptomatic). Study procedures were performed in accordance with the ethical
131 guidelines set forth by the Declaration of Helsinki and local institutional review board (IRB-2004439367).
132 Written informed consent was obtained from all participants before study involvement.

133

134 *Procedures and Instruments*

135 After an initial phone screen, prospective participants were invited for an onsite visit to the Indiana
136 University Human Performance Laboratory. Participants were measured for: standing height (stadiometer),
137 body mass, body composition, resting heart rate (HR), and resting blood pressure. BMI was determined by
138 dividing body mass in kilograms by standing height in meters squared. Body composition was measured
139 via multi-frequency bioelectrical impedance (MC-780U, Tanita Corporation, Tokyo, Japan) to the nearest
140 0.5%. Heart rate and blood pressure were taken from the brachial artery via automated monitoring system
141 (CT40, SunTech Medical, Morrisville, SC). Rate-pressure product (RPP), which provides a non-invasive
142 index of myocardial workload, was calculated by dividing the product of HR and systolic blood pressure by

143 100 [10]. A questionnaire was administered to obtain descriptive information including age (verified by
144 driver's license), education, employment, marital status, yearly income, and current medications. A detailed
145 inventory of SARS-CoV-2 symptoms were also collected.

146 The Profile of Mood States (POMS) was used to assess both specific and general mood. The
147 POMS is a 65 item Likert format (0 = *"not at all"* and "4 = *extremely*) questionnaire that measures the specific
148 mood factors of tension, depression, anger, vigor, fatigue and confusion [14]. A widely used higher order
149 measure of total mood disturbance (TMD) was assessed by adding the negative mood variables and
150 subtracting the positive variable of vigor. Participants completed the POMS on the basis of the standard
151 instructional format (i.e., *"last week including today"*), which yields scores of moderate stability known to be
152 responsive to major interventions including longer-term participation on PA programs. Of note, in situations
153 where researchers are interested in acute mood state responses to an exposure of a single stimulus (e.g.,
154 exercise), the instructional set is altered (i.e., *"how do you feel right now"*) [15]. The norms provided in the
155 POMS are not closely comparable to the present sample, and as such, results from Nyenhuis et al. [16]
156 that assessed the POMS in 400 adults (52% women, age = 44 ± 18 y) were used to standardize scores to
157 a population norm ($Z\text{-score} = \text{observed value} - \text{population mean} / \text{population SD}$). Z-scores were converted
158 to T-scores with a mean of 50 and SD of 10 [$T\text{-score} = 50 + (10 \times Z\text{-score})$].

159 A modified Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ-M) [17] was used to
160 examine functional status at the time of testing. Participants were asked to rate the degree of shortness of
161 breath and fatigue they were experiencing during 10 activities of independent living (e.g., showering, putting
162 on a shirt, preparing a snack, climbing 3 stairs, walking on uneven ground etc.). The Likert-scales were
163 anchored at *"0 = no shortness of breath / fatigue"* and *"10 = very severe shortness of breath / fatigue."* The
164 final section questioned participants about how their involvement in each activity had changed compared
165 to pre-SARS-CoV-2 diagnosis (or over the past 6-months among controls). The scale was anchored at *"0*
166 *= no change"* and *"10 = can no longer perform."* A total score (ranging from 0 to 300) was determined by
167 the summation of all components with a higher score indicating poorer functional status.

168 An eight-item scale was used to measure walking self-efficacy in which participants were asked to
169 rate their level of confidence (0%-100% in 10% increments) in ability to walk at a moderately-fast pace

170 without stopping for 5 min up to 40 min in 5-min increments [18]. Of note, walking self-efficacy is significantly
171 associated with free-living PA and physical functioning cross-sectionally and prospectively [19].

172 The Godin-Shephard Leisure-Time Physical Activity questionnaire was used to measure the
173 frequency of strenuous, moderate, and light leisure-time PA performed for durations of 15 minutes or more
174 over a 7-d period. Participants were asked, “*During a typical 7-d period, how many times on average do*
175 *you do the following kinds of exercise for more than 15 minutes during your free time?*” The frequency for
176 each intensity category was multiplied by the corresponding metabolic equivalents (METs) of 9, 5, and 3
177 for strenuous, moderate, and light, respectively. Resulting scores were totaled for a weekly leisure-score
178 index (LSI).

179

180 *Statistical Analyses*

181 Normality of distributions and data homogeneity were examined with the Shapiro-Wilk and Levene
182 tests, respectively. Data are shown as means and SD. Non-normally distributed data are shown as medians
183 \pm interquartile range (IQR). Between-group differences were evaluated with independent *t*-tests and non-
184 parametric equivalents where appropriate. Substantive differences were determined as a measure of effect
185 size (ES): 0.2 small; 0.5 medium; and 0.8 large. Bivariate correlations were used to examine relationships
186 of interest. The threshold for statistical significance was set *a priori* and defined as two-sided alpha of \leq
187 0.05. Data were analyzed with SPSS (v28; Armonk, NY). Figures were generated using GraphPad Software
188 (v8.3; La Jolla, CA).

189

190

191

192

193

194

195

196

197

198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225

RESULTS

Participants

Descriptive data are shown in Table 1. Consistent with the study design, there were no between-group differences in age, BMI, or body fat%. According to BMI classifications, 14 of 32 (44%) participants were “normal weight” (18.5-24 kg/m²), 12 of 32 (37%) were “overweight” (25-29.9 kg/m²), and 6 of 32 (19%) were “obese” (>30 kg/m²). Diastolic blood pressure ($p = 0.031$, ES = 0.80) and RPP ($p = 0.039$, ES = 0.75) were significantly higher among SARS-CoV-2 participants.

Symptom Frequency and Duration for SARS-CoV-2 Participants

SARS-CoV-2 symptom frequency and duration are shown in Figure 1. Following a positive diagnosis, median time to study enrollment was 85 (IQR: 61) days. Loss of taste/smell, fever/cough, and joint/muscle aches were the most persistent symptoms affecting 71%, 53%, and 41% of participants, respectively. Though fever and sore throat were common – these symptoms tended to be short-lived – fever lasted 1 to 16 days whereas sore throat lasted 2 to 10 days. Of note, 9 of 17 (53%) SARS-CoV-2 participants were *symptomatic* during testing with a median time since diagnosis of 74 (IQR: 67) days.

Between-Group Differences for Functional Status, POMS, and LSI

Though no between-group differences were observed in walking self-efficacy, functional status ($p = 0.008$, ES = 0.23) and LSI ($p = 0.004$, ES = 0.27) were significantly poorer in SARS-CoV-2 participants (Table 1). Significant between-group differences were also detected in POMS TMD (Figure 2) – indicating greater mood disturbance (i.e., more negative mood) in SARS-CoV-2 participants. Three of the six subscales showed SARS-CoV-2 participants had significantly: elevated tension, confusion, and lower vigor (Table 2 and Figure 3).

Relationships between Symptoms, Functional Status, and POMS

The number of symptoms reported at illness onset were positively associated ($r = 0.620$, $p = 0.008$) with confusion (Figure 4A) – interestingly significance persisted, in separate analyses, independent of age ($r = 0.623$, $p = 0.010$) or body fat% ($r = 0.619$, $p = 0.011$). Moreover, functional status was positively

226 associated with the number of days SARS-CoV-2 participants reported loss of taste / smell (Figure 4B).
227 Further examination revealed significant differences between *symptomatic* and *asymptomatic* SARS-CoV-
228 2 participants in walking self-efficacy (median +/- IQR) (asymptomatic; 100 ± 23 vs. symptomatic; 60 ± 43,
229 $p = 0.032$, ES = 0.29) and functional status (median +/- IQR) (asymptomatic; 4 ± 9 vs. symptomatic; 15 ±
230 15, $p = 0.005$, ES = 0.49). Functional status was positively associated with fatigue ($r = 0.491$, $p = 0.045$)
231 among SARS-CoV-2 participants whereas functional status was negatively associated with anger ($r = -$
232 0.585, $p = 0.022$) among control participants. In the total sample, functional status and walking self-efficacy
233 were negatively associated ($r = -0.420$, $p = 0.017$). Additionally, RPP was negatively associated with LSI (r
234 = -0.605, $p < 0.001$) and walking self-efficacy ($r = -0.353$, $p = 0.047$) among all participants.

235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253

254 DISCUSSION

255 The direct and indirect effects of the COVID-19 pandemic remain a concern to personal and public
256 health. Herein, we compared functional status, mood state, and leisure-time PA between women with and
257 without a history of SARS-CoV-2 matched for age, BMI, smoking status, and history of cardiopulmonary
258 disease. In agreement with our hypotheses, SARS-CoV-2 participants reported greater TMD than controls.
259 With respect to normative data, the control group possessed a lower TMD score (i.e., more positive mood),
260 whereas 6 of 17 (35%) SARS-CoV-2 participants exhibited TMD scores above the normative data (i.e.,
261 more negative mood). Significant between-group differences were also found in three of the six POMS sub-
262 scales, in which, the SARS-CoV-2 group reported elevated tension, confusion, and lower vigor. Of note,
263 the confusion scores among SARS-CoV-2 participants were significantly higher than a comparable group
264 of adult women [16]. A significant between-group difference in vigor, but not fatigue was observed, however;
265 research evaluating mood state in response to exercise training suggests fatigue and vigor perform
266 orthogonally rather than as polar endpoints of a single continuum [20].

267 There is a precedent for mental health disturbance in previous coronavirus epidemics including
268 severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) [21]. In these
269 instances, depressed mood and memory impairment were documented during the acute viral infection as
270 well as during varying periods in the post-acute recovery phase among hospitalized individuals. Emerging
271 evidence now suggests SARS-CoV-2 may follow a similar time-course with the number of SARS-CoV-2
272 symptoms reported at illness onset being linked to the development of clinically significant depression,
273 anxiety, and post-traumatic stress symptoms in recovery [22]. Along these lines, we observed the number
274 of reported initial SARS-CoV-2 symptoms were positively associated with confusion sub-scale scores.
275 However, it remains unclear whether related mental health consequences of SARS-CoV-2 are attributable
276 to the direct or indirect effects of the virus. Some have speculated that retrograde axonal transport from
277 peripheral nerves including the gustatory and olfactory nerves may be a route to central nervous system
278 infiltration [23]. In the present work, 12 of 17 (71%) SARS-CoV-2 participants reported loss of taste / smell
279 which corresponded with increased tension ($r = 0.533$, $p = 0.028$) and depression ($r = 0.442$, $p = 0.076$) –
280 providing plausibility for this speculation.

281 To date, limited investigations have evaluated physical functioning in SARS-CoV-2 survivors –
282 particularly among those with post-acute COVID-19 syndrome. It is known that impaired physical function,
283 owing to the effects of dyspnea, fatigue and joint / muscle pain, anxiety, and depression can interfere with
284 the ability to independently perform activities of daily living. Regrettably, this can extend into the realm of
285 personal care such that limited mobility can degrade quality-of-life outcomes. A recent systematic review
286 found that functional ability, as assessed by questionnaire, appears compromised during the acute phase
287 of SARS-CoV-2 [24]. These acute effects are expected given the well-documented respiratory and
288 cardiovascular manifestations of the virus. However, in the present work, post-acute SARS-CoV-2
289 participants had poorer functional status and reported less leisure-time PA compared to controls – despite
290 a median time of 74 days since diagnosis. Notably, functional status (where a higher number corresponds
291 to more disturbance) was positively associated with fatigue among SARS-CoV-2 participants. A possible
292 interpretation of these interrelated factors is that increased feelings of fatigue may complicate activities of
293 daily living, or alternatively, activities of daily living may overburden symptom recovery thereby contributing
294 to increased feelings of fatigue. Hence, periodic assessment of functional status using validated
295 questionnaires such as the PFSQD-M may offer relevant information about the recovery time-course and
296 impact on psychosocial health and quality-of-life in post-acute COVID-19 syndrome.

297 While varying circumstances including preexisting comorbidities can influence the path to recover,
298 there is evidence suggesting women may be disproportionately affected by post-acute COVID-19 syndrome
299 [26,27]. To an extent, it would be expected that advancing age and excess body weight are also risk factors
300 for delayed recovery as occult and/or overt disease are known to increase vulnerability to disease [8]. Sudre
301 and colleagues [27] recently showed that experiencing five or more symptoms during the initial week of
302 illness was associated with an increased risk of post-acute COVID-19 syndrome. Interestingly, in the
303 present work, SARS-CoV-2 participants who were symptomatic at the time of testing reported 5 ± 3
304 symptoms at the time of illness onset. These participants were also found to have lower walking self-efficacy
305 and poorer functional status independent of age or BMI (compared to asymptomatic SARS-CoV-2
306 participants). Thus, it seems functional impairment accompanying post-acute COVID-19 syndrome may be
307 worse in individuals wherein the SARS-CoV-2 virus elicited more symptoms reported during acute illness.

308 It is understandable that persistent SARS-CoV-2 symptoms are likely to degrade functional status
309 while also inciting feelings of concern about health and well-being. Indeed, leisure-time PA was negatively
310 associated ($r = -0.672$, $p = 0.047$) with the number of symptoms among symptomatic SARS-CoV-2
311 participants in the present work. This finding is consistent with process of interoception wherein peripheral
312 (sensory) feedback provides a moment-to-moment updates of the internal bodily environment [28]. This, in
313 turn, has the potential to trigger a maladaptive cycle that can ultimately interfere with activities of daily living.
314 Given that some SARS-CoV-2 symptoms, notably cough and joint/muscle aches can last beyond 3-4
315 months, systemic deconditioning may become a lasting complication. This becomes especially important
316 considering women already tend to exhibit greater rates of age-related disability than men [7] – and female
317 sex is a risk factor for persistent SARS-CoV-2 symptoms [27]. Within this context, further work is needed
318 to develop and implement targeted interventions to offset the burden of deconditioning in post-acute
319 COVID-19 syndrome.

320 *Limitations*

321 To our knowledge, no prior work has examined constructs of mental and physical health in SARS-
322 CoV-2 while employing a case-control design matching participants on age, BMI, smoking status, and
323 history of cardiopulmonary disease. As such, we have reasonable confidence that our observations are due
324 to meaningful between-group differences in functional status, mood state, and leisure-time PA.
325 Nevertheless, there are several limitations that need to be considered. First, the retrospective nature of the
326 work limits our ability to know whether alterations in the observed outcomes were present before testing.
327 Second, because the study sample was purposely limited to women, findings may not be generalizable to
328 men. Third, since antibody testing was not performed, it is unknown if control participants might have
329 unknowingly had a prior SARS-CoV-2 infection. Lastly, we acknowledge a relatively small sample size.
330 However, given the strength of the reported effect sizes – we reached statistical significance across multiple
331 measures. Future work should examine prospective, longitudinal changes in functional status, mood state,
332 and leisure-PA in post-acute COVID-19 syndrome while taking into consideration the related impact on
333 quality-of-life and objective measures of PA. Such information will prove useful in our collective
334 understanding about the sequela of persistent symptoms that can undermine mental and physical health in
335 post-acute COVID-19 syndrome.

336 *Conclusions*

337 The present work extends the growing evidence highlighting the adverse consequences of post-
338 acute COVID-19 syndrome on mental health and functional status in women. We report greater TMD –
339 attributed to increased tension, increased confusion, and decreased vigor in SARS-CoV-2 participants.
340 Likewise, poorer functional status was noted which was positively associated with fatigue among SARS-
341 CoV-2 participants. Interestingly, among SARS-CoV-2 participants, the number of symptoms reported at
342 illness onset were positively associated with confusion.

343 *Acknowledgements*

344 The authors greatly appreciate the recruitment efforts of the Indiana Clinical and Translational
345 Sciences Institute's All IN for Health team and Tyler B. Baker for his assistance with data collection.

346 *Author Contributions*

347 All testing was performed in the Human Performance Laboratory at the Indiana University School
348 of Public Health – Bloomington. SJC and MNB conceptualized the study design. SJC obtained funding,
349 provided supervision of experimental testing, performed data analyses, and drafted the original manuscript.
350 MNB conducted experimental testing, completed data analyses, generated figures, and provided revisions
351 to manuscript drafts. JSR, BAP, and BLP gave guidance, contributed intellectual content, and provided
352 revisions to manuscript drafts. All authors approved of the final version of the manuscript.

353

354

355

356

357

358

359

360

361

362

363

364

365

REFERENCES

- 366 1. Dong E, Du H, Gardner L An interactive web-based dashboard to track COVID-19 in real time. *Lancet*
367 *Infect Dis* 2020; 20:533-534.
- 368 2. O'Dowd A Covid-19: Cases of delta variant rise by 79%, but rate of growth slows. *BMJ* 2021;
369 373:n1596.
- 370 3. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-
371 19 syndrome. *Nat Med* 2021; 27:601-615.
- 372 4. Yan Z, Yang M, Lai CL Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various
373 Organ Systems and Recommendation on Rehabilitation Plans. *Biomedicines* 2021; 9:966. doi:
374 10.3390/biomedicines9080966.
- 375 5. Vanichkachorn G, Newcomb R, Cowl CT, Murad MH, Breeher L, Miller S, et al. Post-COVID-19
376 Syndrome (Long Haul Syndrome): Description of a Multidisciplinary Clinic at Mayo Clinic and
377 Characteristics of the Initial Patient Cohort. *Mayo Clin Proc* 2021; 96:1782-1791.
- 378 6. Davido B, Seang S, Tubiana R, de Truchis P Post-COVID-19 chronic symptoms: a postinfectious
379 entity? *Clin Microbiol Infect* 2020; 26:1448-1449.
- 380 7. Hosseinpoor AR, Williams JS, Jann B, Kowal P, Officer A, Posarac A, et al. Social determinants of sex
381 differences in disability among older adults: a multi-country decomposition analysis using the World
382 Health Survey. *Int J Equity Health* 2012; 11:52-9276-11-52.
- 383 8. Carter SJ, Baranauskas MN, Fly AD Considerations for Obesity, Vitamin D, and Physical Activity Amid
384 the COVID-19 Pandemic. *Obesity (Silver Spring)* 2020; 28:1176-1177.
- 385 9. Wilke J, Mohr L, Tenforde AS, Edouard P, Fossati C, González-Gross M, et al. A Pandemic within the
386 Pandemic? Physical Activity Levels Substantially Decreased in Countries Affected by COVID-19. *Int J*
387 *Environ Res Public Health* 2021; 18:2235. doi: 10.3390/ijerph18052235.
- 388 10. Smith L, Jacob L, Yakkundi A, McDermott D, Armstrong NC, Barnett Y, et al. Correlates of symptoms
389 of anxiety and depression and mental wellbeing associated with COVID-19: a cross-sectional study of
390 UK-based respondents. *Psychiatry Res* 2020; 291:113138.
- 391 11. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment
392 Guidelines. National Institutes of Health. Available at <http://www.covid19treatmentguidelines.nih.gov/>.
393 Accessed [10/13/2021].
- 394 12. Datta SD, Talwar A, Lee JT A Proposed Framework and Timeline of the Spectrum of Disease Due to
395 SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. *JAMA* 2020;
396 324:2251-2252.
- 397 13. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L Management of post-acute covid-19 in
398 primary care. *BMJ* 2020; 370:m3026.
- 399 14. McNair DM, Lorr M, Droppleman LF Manual profile of mood states. 1971.

- 400 15. Berger BG, Motl RW Exercise and mood: A selective review and synthesis of research employing the
401 profile of mood states. *Journal of applied sport psychology* 2000; 12:69-92.
- 402 16. Nyenhuis DL, Yamamoto C, Luchetta T, Terrien A, Parmentier A Adult and geriatric normative data
403 and validation of the profile of mood states. *J Clin Psychol* 1999; 55:79-86.
- 404 17. Lareau SC, Meek PM, Roos PJ Development and testing of the modified version of the pulmonary
405 functional status and dyspnea questionnaire (PFSDQ-M). *Heart Lung* 1998; 27:159-168.
- 406 18. McAuley E, Blissmer B, Katula J, Duncan TE Exercise environment, self-efficacy, and affective
407 responses to acute exercise in older adults. *Psychology and Health* 2000; 15:341-355.
- 408 19. McAuley E, Konopack JF, Morris KS, Motl RW, Hu L, Doerksen SE, et al. Physical activity and
409 functional limitations in older women: influence of self-efficacy. *J Gerontol B Psychol Sci Soc Sci* 2006;
410 61:P270-7.
- 411 20. Kenttä G, Hassmén P, Raglin JS Mood state monitoring of training and recovery in elite kayakers.
412 *European Journal of Sport Science* 2006; 6:245-253.
- 413 21. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and
414 neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and
415 meta-analysis with comparison to the COVID-19 pandemic. *Lancet Psychiatry* 2020; 7:611-627.
- 416 22. Ismael F, Bizario JCS, Battagin T, Zaramella B, Leal FE, Torales J, et al. Post-infection depressive,
417 anxiety and post-traumatic stress symptoms: A prospective cohort study in patients with mild COVID-19.
418 *Prog Neuropsychopharmacol Biol Psychiatry* 2021; 111:110341.
- 419 23. Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L, Dubé M, et al. Human
420 Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central
421 Nervous System? *Viruses* 2019; 12:14. doi: 10.3390/v12010014.
- 422 24. Pizarro-Pennarolli C, Sánchez-Rojas C, Torres-Castro R, Vera-Urbe R, Sanchez-Ramirez DC,
423 Vasconcello-Castillo L, et al. Assessment of activities of daily living in patients post COVID-19: a
424 systematic review. *PeerJ* 2021; 9:e11026.
- 425 25. Townsend L, Dowds J, O'Brien K, Sheill G, Dyer AH, O'Kelly B, et al. Persistent Poor Health after
426 COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. *Ann Am Thorac*
427 *Soc* 2021; 18:997-1003.
- 428 26. González-Hermosillo JA, Martínez-López JP, Carrillo-Lampón SA, Ruiz-Ojeda D, Herrera-Ramírez S,
429 Amezcua-Guerra LM, et al. Post-Acute COVID-19 Symptoms, a Potential Link with Myalgic
430 Encephalomyelitis/Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort. *Brain Sci* 2021;
431 11:760. doi: 10.3390/brainsci11060760.
- 432 27. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and
433 predictors of long COVID. *Nat Med* 2021; 27:626-631.
- 434 28. Paulus MP, Feinstein JS, Khalsa SS An active inference approach to interoceptive psychopathology.
435 *Annual review of clinical psychology* 2019; 15:97-122.
- 436

437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470


Figure 1. Symptoms reported by SARS-CoV-2 participants. The duration (days) and frequency n (%) of symptoms reported after illness onset. Note the protracted duration in cough and joint / muscle aches.

Figure 2. Between-group differences in Total Mood Disturbance (TMD) T-scores from the Profile of Mood States (POMS). $**p < 0.01$. Means and 95% confidence intervals: SARS-CoV-2, 49.6 (46.2 to 53.1) vs. controls, 43.4 (41.7 to 45.5).

Figure 3. Profile of Mood States (POMS) sub-scale T-scores between SARS-CoV-2 and control participants. $*p < 0.05$. $***p < 0.001$. Means and 95% confidence intervals. *Tension*: SARS-CoV-2, 52.0 (47.9 to 57.0) vs. controls, 44.2 (41.6 to 46.8); *Vigor*: SARS-CoV-2, 44.4 (39.2 to 49.1) vs. controls, 51.4 (47.3 to 55.5); *Confusion*: SARS-CoV-2, 51.7 (48.0 to 56.3) vs. controls, 44.0 (41.9 to 46.6).

Figure 4. A) Unadjusted scatterplot between number of symptoms reported after illness onset and confusion T-score. B) unadjusted scatterplot between functional status and number of days experiencing loss of taste / smell.

471 Figure 1.



472

473 Figure 2.

474

475

476

477

478

479

480

481

482


483

484


485

486

487



488 Figure 3.



489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504

505 Figure 4.

506

507





Table 1. Descriptives ($n = 32$).

Variables	SARS-CoV-2 $n = 17$	Controls $n = 15$	p -value	ES
Age (y)	55 ± 11	54 ± 14	0.814	
Height (m)	1.64 ± 0.04	1.61 ± 0.07	0.263	
Mass (kg)	75 ± 20	67 ± 10	0.170	
BMI (kg/m ²)	27.9 ± 7.0	25.9 ± 4.4	0.343	
Body Fat (%)	33.7 ± 7.4	32.1 ± 7.7	0.554	
HR (bpm)	71 ± 13	66 ± 8	0.167	
SBP (mm Hg)	126 ± 9	118 ± 11	0.051	
DBP (mm Hg)	82 ± 9	75 ± 7	0.031†	0.78
Rate-pressure product	89 ± 17	77 ± 13	0.039†	0.75
PFSDQ-M [median (IQR)]‡	10 (14)	2 (3)	0.008†	0.23
Walking Self-Efficacy [median (IQR)]	81 (44)	95 (18)	0.274	
Leisure Score Index [median (IQR)]	21 (18)	36 (22)	0.004†	0.27
Depression Medications (yes) [n (%)]	6 (35)	1 (7)	0.051	
Employed (yes) [n (%)]	11 (65)	11 (73)	0.599	
Marital Status [n (%)]				
Married or living with sig. other	11 (65)	11 (73)	0.599	
Education				
Bachelor's Degree (yes) [n (%)]	11 (65)	13 (87)	0.152	
Annual Income [n (%)]				
≥ \$50k	13 (76)	12 (80)	0.810	

Values are shown as means and SD unless noted otherwise. ES, effect size; BMI, body mass index; HR, heart rate; bpm, beats per min; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure; mm Hg, millimeters per mercury; Rate-pressure product calculated by dividing the product of HR and SBP by 100. IQR, interquartile range. PFSDQ-M, Pulmonary Functional Status and Dyspnea Questionnaire. ‡higher number indicative of greater disturbance. †Statistically significant between-group difference at P -value ≤ 0.050 .

Table 2. Profile of Mood States Raw Scores ($n = 32$)

POMS Score	SARS-CoV-2 $n = 17$	Controls $n = 15$	p -value	ES
TMD	19 ± 24	-1 ± 12	0.005†	1.0
Tension [median (IQR)]	7 (12)	5 (4)	0.009†	0.9
Depression [median (IQR)]	3 (11)	3 (3)	0.262	
Anger	6 ± 5	3 ± 2	0.132	
Vigor	15 ± 6	20 ± 6	0.043†	0.7
Fatigue	6 ± 6	4 ± 4	0.265	
Confusion [median (IQR)]	6 (4)	3 (2)	0.005†	1.1

Values are shown as means and SD unless noted otherwise. POMS, Profile of Mood States; ES, effect size; TMD, total mood disturbance. IQR, interquartile range. †Statistically significant between-group differences at p -value ≤ 0.05 .